Nancy M. Paris, President and CEO
Angie Patterson, Vice President
Georgia CORE Center for Oncology Research and Education
Presentation to Georgia Senate Women's Adequate Healthcare Study Committee
www.gacommissiononwomen.org
A presentation looking at breast health and BreastScreen Victoria. The presentation covers breast cancer, risks of breast cancer, breast awareness and the BreastScreen Victoria pathway.
Dr. Brenda Fitzgerald, Commissioner and State Health Officer, Georgia Department of Public Health
Presentation to the Senate Women's Adequate Healthcare Study Committee
www.gacommissiononwomen.org
Adrienne D. Zertuche, MD, MPH
Georgia Maternal and Infant Health Research Group
Georgia Obstetrical and Gynecological Society
Presentation to the Georgia Senate Women's Adequate Healthcare Study Committee
www.gacommissiononwomen.org
Sharad Ghamande, MD, FACOG
Professor and Director of Gynecologic Oncology
Augusta University Cancer Center
Presentation to the Georgia Senate Women's Adequate Healthcare Study Committee
www.gacommissiononwomen.org
Pat Cota, Executive Director
Georgia Obstetrics and Gynecology Society
Presentation to the Georgia Senate Women's Adequate Healthcare Study Committee
November 9, 2015
Nancy M. Paris, President and CEO
Angie Patterson, Vice President
Georgia CORE Center for Oncology Research and Education
Presentation to Georgia Senate Women's Adequate Healthcare Study Committee
www.gacommissiononwomen.org
A presentation looking at breast health and BreastScreen Victoria. The presentation covers breast cancer, risks of breast cancer, breast awareness and the BreastScreen Victoria pathway.
Dr. Brenda Fitzgerald, Commissioner and State Health Officer, Georgia Department of Public Health
Presentation to the Senate Women's Adequate Healthcare Study Committee
www.gacommissiononwomen.org
Adrienne D. Zertuche, MD, MPH
Georgia Maternal and Infant Health Research Group
Georgia Obstetrical and Gynecological Society
Presentation to the Georgia Senate Women's Adequate Healthcare Study Committee
www.gacommissiononwomen.org
Sharad Ghamande, MD, FACOG
Professor and Director of Gynecologic Oncology
Augusta University Cancer Center
Presentation to the Georgia Senate Women's Adequate Healthcare Study Committee
www.gacommissiononwomen.org
Pat Cota, Executive Director
Georgia Obstetrics and Gynecology Society
Presentation to the Georgia Senate Women's Adequate Healthcare Study Committee
November 9, 2015
Lucy Marion, PhD, RN
Dean, College of Nursing
Augusta University
Presentation to the Georgia Senate Women's Adequate Healthcare Study Committee
www.gacommissiononwomen.org
Just Diagnosed: What to Expect, What to Know, and What to do Nextbkling
Have you recently been diagnosed with breast cancer and need help navigating the diagnosis? Join author Arlene Karole as she discusses her new book Just Diagnosed: What to Expect, What to Know, and What to do Next.
Nicole S. Carlson, PhD, CNM
President, Georgia Affiliate of American College of Nurse-Midwives
Assistant Professor, Emory University School of Nursing
Presentation to the Georgia Senate Women's Adequate Healthcare Study Committee
November 9, 2015
Lucy Marion, PhD, RN, FAAN, FAANP
Dean, College of Nursing, Augusta University
Chair, APRN Task Force of Georgia Nursing Leadership Coalition
Presentation to the Georgia Senate Women's Adequate Healthcare Study Committee
CANSA places the focus on the ‘Big 5’ cancers affecting SA men during its Men’s Health Awareness Campaign in November, namely, prostate, colorectal, Kaposi sarcoma (a type of skin cancer), lung and bladder cancer. However, it’s vital that men be pro-active, stepping up and taking responsibility for their health all year round.
Read more: http://www.cansa.org.za/mens-health/
mathernal health on 4 delays during facility services by Girma Huka DukaleGirmaaHuqqaa
This power point is used for students,teacher,and for any organization those like to use as references of their study.The portion of this part should not transmitted in any means to without permission of this group.
Infertility is the inability of a sexually active, non-contracepting couple to achieve pregnancy in one year. The male partner can be evaluated for infertility or subfertility using a variety of clinical interventions, and also from a laboratory evaluation of semen.
Why was screening implemented?
What is overdiagnosis?
The evidence for overdiagnosis
Available data
Facts from recent studies
Risks of screening
The illusion of early detection
Harms due to overdiagnosis
Benefit-risk balance
So, what to do?
About mammograms: https://desdaughter.wordpress.com/tag/mammograms/
About overdiagnosis: https://desdaughter.wordpress.com/tag/overdiagnosis/
About screening: https://desdaughter.wordpress.com/tag/screening/
D. Stephen Goggans, MD, MPH
District Health Director - East Central District
Georgia Department of Public Health
Presentation to the Georgia Senate Women's Adequate Healthcare Study Committee
www.gacommissiononwomen.org
MDG is millineum development goals and 4/5 relate to women care and neonatal care..the deadline to achieve health targets is reset for 2015, but we in south east asia are still far away from these targets.....see who has done it and who will
Oluwayemisi Ishola: Contraceptive Use Autonomy, Decision and Dependence Level...GetItTogetherNG
This abstract was presented by The Challenge Initiative (TCI) at the 6th Nigeria Family Planning Conference which happened in Abuja from December 7 - 11, 2020.
Lucy Marion, PhD, RN
Dean, College of Nursing
Augusta University
Presentation to the Georgia Senate Women's Adequate Healthcare Study Committee
www.gacommissiononwomen.org
Just Diagnosed: What to Expect, What to Know, and What to do Nextbkling
Have you recently been diagnosed with breast cancer and need help navigating the diagnosis? Join author Arlene Karole as she discusses her new book Just Diagnosed: What to Expect, What to Know, and What to do Next.
Nicole S. Carlson, PhD, CNM
President, Georgia Affiliate of American College of Nurse-Midwives
Assistant Professor, Emory University School of Nursing
Presentation to the Georgia Senate Women's Adequate Healthcare Study Committee
November 9, 2015
Lucy Marion, PhD, RN, FAAN, FAANP
Dean, College of Nursing, Augusta University
Chair, APRN Task Force of Georgia Nursing Leadership Coalition
Presentation to the Georgia Senate Women's Adequate Healthcare Study Committee
CANSA places the focus on the ‘Big 5’ cancers affecting SA men during its Men’s Health Awareness Campaign in November, namely, prostate, colorectal, Kaposi sarcoma (a type of skin cancer), lung and bladder cancer. However, it’s vital that men be pro-active, stepping up and taking responsibility for their health all year round.
Read more: http://www.cansa.org.za/mens-health/
mathernal health on 4 delays during facility services by Girma Huka DukaleGirmaaHuqqaa
This power point is used for students,teacher,and for any organization those like to use as references of their study.The portion of this part should not transmitted in any means to without permission of this group.
Infertility is the inability of a sexually active, non-contracepting couple to achieve pregnancy in one year. The male partner can be evaluated for infertility or subfertility using a variety of clinical interventions, and also from a laboratory evaluation of semen.
Why was screening implemented?
What is overdiagnosis?
The evidence for overdiagnosis
Available data
Facts from recent studies
Risks of screening
The illusion of early detection
Harms due to overdiagnosis
Benefit-risk balance
So, what to do?
About mammograms: https://desdaughter.wordpress.com/tag/mammograms/
About overdiagnosis: https://desdaughter.wordpress.com/tag/overdiagnosis/
About screening: https://desdaughter.wordpress.com/tag/screening/
D. Stephen Goggans, MD, MPH
District Health Director - East Central District
Georgia Department of Public Health
Presentation to the Georgia Senate Women's Adequate Healthcare Study Committee
www.gacommissiononwomen.org
MDG is millineum development goals and 4/5 relate to women care and neonatal care..the deadline to achieve health targets is reset for 2015, but we in south east asia are still far away from these targets.....see who has done it and who will
Oluwayemisi Ishola: Contraceptive Use Autonomy, Decision and Dependence Level...GetItTogetherNG
This abstract was presented by The Challenge Initiative (TCI) at the 6th Nigeria Family Planning Conference which happened in Abuja from December 7 - 11, 2020.
High cost involved in establishing and maintaining a good ART laboratory, the constant need to upgrade and adopt new technology and the use of stimulation protocols that use expensive drugs, makes ART treatment expensive.
Effectiveness of vitamin A supplementation for preventing morbidity and morta...Health Evidence™
Health Evidence™ hosted a 60 minute webinar examining the effectiveness of vitamin A supplementation for preventing morbidity and mortality in children from six months to five years of age. Click here for access to the audio recording for this webinar: https://youtu.be/fuWd7TJQYEI
Dr. Aamer Imdad, MBBS, MPH, Assistant Professor of Pediatrics, SUNY Upstate Medical University led the session and presented findings from their recent Cochrane review:
Imdad A, Mayo-Wilson E, Herzer K, & Bhutta Z. (2017). Vitamin A supplementation for preventing morbidity and mortality in children from six months to five years of age. Cochrane Database of Systematic Reviews, 2017(3), CD008524.
Vitamin A deficiency is a major public health problem in low- and middle-income countries, affecting 190 million children under five years of age and leading to many adverse health consequences, including death. This review examines the effectiveness of vitamin A supplementation (VAS) for preventing morbidity and mortality in children aged six months to five years. Forty-seven randomized control trials involving approximately 1,223,856 children were included in this review. VAS was associated with a clinically meaningful reduction in morbidity and mortality in children.
Gayle Jameson, MSN, ACNP-BC, AOCN, Jessica MacIntyre, MSN, APRN, NP-C, AOCNP, and Megan Price, MSN, NP-C, prepared useful practice aids pertaining to pancreatic cancer for this CNE activity titled, "Clinical Advances in Pancreatic Cancer: The Oncology Nurse as a Leader and Advocate for Patients in a Changing Therapeutic Landscape." For the full presentation, monograph, complete CNE information, and to apply for credit, please visit us at http://bit.ly/2E2t05c. CNE credit will be available until May 21, 2020.
2nd Annual Oncology Asia
Date: 7 – 9 September 2015 | Sheraton Miyako, Tokyo, Japan
www.oncologyasia.com
The 2nd Annual Oncology Asia zeroes in on the latest cutting edge developments in oncology drug discovery and late phase strategies to get oncology drugs to market faster! Under the Drug Discovery track, this conference will discuss latest immune checkpoint inhibitor combinations, preclinical development trends, novel biomarkers and oncology drug development case studies in Asia. Under the late phase track, it will discuss pricing for success, global and regional commercialization case studies, healthcare policy updates and pricing for success.
Find out about the latest drug discovery trends along with latest strategies for global and regional commercialization at the ONLY senior industry gathering focused on advancing cutting edge oncology R&D and commercialization strategies for Asia in Tokyo, Japan!
Advance in diagnosis & treatment of cancers has led to high cure rate & longer survival.
Nearly 1 in 12 cases detected before 40 years age.
Survivors have to face infertility or early menopause.
Jennifer Mason, Senior Advisor for FP/HIV Integration for USAID's Office of Population and Reproductive Health describes the agency's approach to integrating family planning services with HIV health services and provides country examples of integration practices.
Why you should attend:
1. Learn from in-depth case studies on strategic partnering and effective collaboration
2. Explore new business opportunities and strategies to reach the biosimilars market in the region
3. Gain insights into the regulatory landscape for biosimilars in China, India, Korea, Taiwan and more
4. Gather the latest market intelligence and analysis and identify new trends and opportunities in Biosimilars R&D, contract manufacturing and commercialization in Asia
报名参加的五大理由
1. 深入学习有关与亚洲公司建立战略合作和有效协作的案例研究
2. 探索新的商机和战略,以便进入当地的生物仿制药市场
3. 深入了解中国、印度、韩国、台湾以及更多国家或地区的生物仿制药监管形势
4. 收集最新的市场情报和分析,确定生物仿制药研发、合同制造和商业化在亚洲的新趋势和机会
Hear about:
Biopharma Regulatory Updates and Development
Victoria Elegant, VP Medical & Regulatory Affairs, Baxter, China
Andrea Laslop, Head of Scientific Office, Austrian Agency for Food and Health Safety, Austrian Member, European Medicines Agency
Arvind Mishra, Global Head of Quality & Regulatory & Head of Strategic Business Unit, Biologicals, Cadilla Pharmaceutical, India
Advances in Biosimilars R&D
Jeffrey Su, CSO, Cytovance Biologics, USA
Wenzhi Tian, CEO, Huabo Biopharma, China
Ming Wang, President and COO, Gan & Lee Pharmaceuticals, China
Feng Li, CEO, Beijing Mabworks, China
Shaligram Rane, Vice President for Quality, Intas Pharmaceuticals, India
Understanding Obstacles and Hurdles for Entering the Biosimilars Market
Khai Meng Ang, Vice President Asia, Hospira, China
Jason Li, Senior Director, Genor Biopharma, China
Sachidananda Moorthy, Vice President - Clinical Research, Medical and Regulatory Affairs, Avesthagen, India
Sameer Agarwal, Senior Vice President, Business Center Strategic Marketing, Business Unit Generic Drugs & Standard Solutions, Fresenius Kabi, Germany
What can Asia Learn from Global Biosimilars Development and Litigation?
Li Cai, Regional R&D Counsel, Pfizer, China
Vivek Mittal, Head – Legal, Lupin, India
Viren Mahurkar, Managing Director, HitechnRock Advisors, Singapore
http://www.biosimilarsasia.com
Pre-Conference Special Focus Day, 20 May 2014
Clinical Development for Biosimilars
Post-Conference Workshops, 23 May 2014
A: Challenges in Demonstrating Biosimilarity and Interchangeability of Biosimilar Products
B: Successfully Bringing Biosimilars to Market
会前特别关注日,2014 年 5 月 20 日
生物仿制药的临床开发
会后研讨会,2014 年 5 月 23 日
A:在展示生物仿制药产品的生物相似性和可互换性方面所面临的挑战
B:成功地将生物仿制药推向市场
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
Defecation
Normal defecation begins with movement in the left colon, moving stool toward the anus. When stool reaches the rectum, the distention causes relaxation of the internal sphincter and an awareness of the need to defecate. At the time of defecation, the external sphincter relaxes, and abdominal muscles contract, increasing intrarectal pressure and forcing the stool out
The Valsalva maneuver exerts pressure to expel faeces through a voluntary contraction of the abdominal muscles while maintaining forced expiration against a closed airway. Patients with cardiovascular disease, glaucoma, increased intracranial pressure, or a new surgical wound are at greater risk for cardiac dysrhythmias and elevated blood pressure with the Valsalva maneuver and need to avoid straining to pass the stool.
Normal defecation is painless, resulting in passage of soft, formed stool
CONSTIPATION
Constipation is a symptom, not a disease. Improper diet, reduced fluid intake, lack of exercise, and certain medications can cause constipation. For example, patients receiving opiates for pain after surgery often require a stool softener or laxative to prevent constipation. The signs of constipation include infrequent bowel movements (less than every 3 days), difficulty passing stools, excessive straining, inability to defecate at will, and hard feaces
IMPACTION
Fecal impaction results from unrelieved constipation. It is a collection of hardened feces wedged in the rectum that a person cannot expel. In cases of severe impaction the mass extends up into the sigmoid colon.
DIARRHEA
Diarrhea is an increase in the number of stools and the passage of liquid, unformed feces. It is associated with disorders affecting digestion, absorption, and secretion in the GI tract. Intestinal contents pass through the small and large intestine too quickly to allow for the usual absorption of fluid and nutrients. Irritation within the colon results in increased mucus secretion. As a result, feces become watery, and the patient is unable to control the urge to defecate. Normally an anal bag is safe and effective in long-term treatment of patients with fecal incontinence at home, in hospice, or in the hospital. Fecal incontinence is expensive and a potentially dangerous condition in terms of contamination and risk of skin ulceration
HEMORRHOIDS
Hemorrhoids are dilated, engorged veins in the lining of the rectum. They are either external or internal.
FLATULENCE
As gas accumulates in the lumen of the intestines, the bowel wall stretches and distends (flatulence). It is a common cause of abdominal fullness, pain, and cramping. Normally intestinal gas escapes through the mouth (belching) or the anus (passing of flatus)
FECAL INCONTINENCE
Fecal incontinence is the inability to control passage of feces and gas from the anus. Incontinence harms a patient’s body image
PREPARATION AND GIVING OF LAXATIVESACCORDING TO POTTER AND PERRY,
An enema is the instillation of a solution into the rectum and sig
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
1. Breast Cancer Awareness:
Pivotal Role of Self
Examination
Dr. Sobia Khalid
Assistant Professor
Histopathology
University of Health Sciences, Lahore.
6. WHY Pakistan lacks statistics?
• Lack of access to adequate diagnostic services.
• Lack of access to treatment of breast cancer throughout
Pakistan other than a few metro cities
• Unavailability and unaffordability of Chemo, Radiation and
Targeted Therapies
• Medicines of Breast Cancer are highly expensive
• Molecules that are used in breast cancer treatment are
expensive and all of them are not available in Pakistan
• Breast Cancer is not included in Health Card issued by
Government of Pakistan
• Baitul-Mal caters a small fraction of needy breast cancer
patients
• There is no National Cancer Registry available in Pakistan
• There is no National Cancer Prevention Programme in
16. MAMMAPRINT 70-GENE
Prognostic Assay
The MammaPrint assay is designed to
identify younger breast cancer patients at
low risk for distant metastasis, who might
consequently be spared systemic
treatment.
The 70 genes that comprise the
MammaPrint assay are focused primarily
on proliferation, with additional genes
associated with invasion, metastasis,
stromal integrity and angiogenesis.
17. WHAT TO DO
• Recommendations for the government of Pakistan
• To waive off custom duties on diagnostic equipment,
especially Mammogram and Ultrasound Machines
• Diagnostic facilities should be available, at least at the DHQ
level
• Breast Cancer treatment to be prioritised in the health budget
• Inclusion of Breast Cancer treatment in health card issued by
the Government
• Subsidise breast cancer medicines or abolish taxes and
duties
• Allow Import of all Molecules for the Treatment of Breast
Cancer and waive off custom duties too
• Cancer-causing ingredients that are used in food should be
banned in Pakistan